AIMS: This is a multisite, 12-week, open-label trial of lamotrigine augmentation in 57 older adults (≥ 60 years; mean ± SD age = 66.5 ± 6.7 years) with either type I or type II bipolar depression. METHODS: Primary outcome measure was change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary outcome measures included Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression-Bipolar version (CGI-BP), and the WHO-Disability Assessment Schedule II (WHO-DAS II). The Udvalg for Kliniske Undersøgelser (UKU) was used to assess side effects. RESULTS: A total of 77.2% of the study subjects had bipolar I disorder. The mean (SD) lamotrigine dose was 150.9 (68.5) mg/day. There was significant improvement in the MADRS, HAM-D, CGI-BP, and in most domains on the WHO-DAS II. For patients for whom final MADRS score was available: 31 (57.4%) met remission criteria and 35 (64.8%) met response criteria. There were 19/57 (33.3%) who dropped out of the study prematurely, with 6 dropouts due to adverse events (4 cases of rash, 1 manic switch, and 1 hyponatremia). Two cases of rash were possibly drug related and were resolved with drug discontinuation. The most common UKU adverse effects were reduced sleep duration (n = 14, 24.6%), weight loss (n = 12, 21.1%), increased dream activity (n = 12, 21.1%), polyuria/polydipsia (n = 11, 19.3%), weight gain (n = 9, 15.8%), diminished sexual desire (n = 9, 15.8%), increased sleep (n = 9, 15.8%), lassitude/fatigue (n = 8, 14%), and unsteady gait (n = 8, 14%). No significant changes in electrocardiogram or laboratory tests were observed. CONCLUSIONS: In bipolar depressed elders, lamotrigine was associated with improvement in depression, psychopathology, and functional status. There was a moderate number of adverse events, although relationship of adverse events (particularly falls) to study medication could not be clearly determined in this uncontrolled trial. Controlled studies are needed to further evaluate efficacy and tolerability of lamotrigine therapy in geriatric bipolar depression.
AIMS: This is a multisite, 12-week, open-label trial of lamotrigine augmentation in 57 older adults (≥ 60 years; mean ± SD age = 66.5 ± 6.7 years) with either type I or type II bipolar depression. METHODS: Primary outcome measure was change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary outcome measures included Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression-Bipolar version (CGI-BP), and the WHO-Disability Assessment Schedule II (WHO-DAS II). The Udvalg for Kliniske Undersøgelser (UKU) was used to assess side effects. RESULTS: A total of 77.2% of the study subjects had bipolar I disorder. The mean (SD) lamotrigine dose was 150.9 (68.5) mg/day. There was significant improvement in the MADRS, HAM-D, CGI-BP, and in most domains on the WHO-DAS II. For patients for whom final MADRS score was available: 31 (57.4%) met remission criteria and 35 (64.8%) met response criteria. There were 19/57 (33.3%) who dropped out of the study prematurely, with 6 dropouts due to adverse events (4 cases of rash, 1 manic switch, and 1 hyponatremia). Two cases of rash were possibly drug related and were resolved with drug discontinuation. The most common UKU adverse effects were reduced sleep duration (n = 14, 24.6%), weight loss (n = 12, 21.1%), increased dream activity (n = 12, 21.1%), polyuria/polydipsia (n = 11, 19.3%), weight gain (n = 9, 15.8%), diminished sexual desire (n = 9, 15.8%), increased sleep (n = 9, 15.8%), lassitude/fatigue (n = 8, 14%), and unsteady gait (n = 8, 14%). No significant changes in electrocardiogram or laboratory tests were observed. CONCLUSIONS: In bipolar depressed elders, lamotrigine was associated with improvement in depression, psychopathology, and functional status. There was a moderate number of adverse events, although relationship of adverse events (particularly falls) to study medication could not be clearly determined in this uncontrolled trial. Controlled studies are needed to further evaluate efficacy and tolerability of lamotrigine therapy in geriatric bipolar depression.
Authors: Robert C Young; Herbert C Schulberg; Ariel G Gildengers; Martha Sajatovic; Benoit H Mulsant; Laszlo Gyulai; John Beyer; Lauren Marangell; Mark Kunik; Thomas Ten Have; Martha L Bruce; Ruben Gur; Patricia Marino; Jovier D Evans; Charles F Reynolds; George S Alexopoulos Journal: Bipolar Disord Date: 2010-02 Impact factor: 6.744
Authors: Joseph R Calabrese; Russell F Huffman; Robin L White; Suzanne Edwards; Thomas R Thompson; John A Ascher; Eileen T Monaghan; Robert A Leadbetter Journal: Bipolar Disord Date: 2008-03 Impact factor: 6.744
Authors: Janet B W Williams; Kenneth A Kobak; Per Bech; Nina Engelhardt; Ken Evans; Joshua Lipsitz; Jason Olin; Jay Pearson; Amir Kalali Journal: Int Clin Psychopharmacol Date: 2008-05 Impact factor: 1.659
Authors: Barnett S Meyers; Alastair J Flint; Anthony J Rothschild; Benoit H Mulsant; Ellen M Whyte; Catherine Peasley-Miklus; Eros Papademetriou; Andrew C Leon; Moonseong Heo Journal: Arch Gen Psychiatry Date: 2009-08
Authors: Marc L M van der Loos; Paul G H Mulder; Erwin G Th M Hartong; Marc B J Blom; Anton C Vergouwen; Herman J U E M de Keyzer; Peter J H Notten; Marijke L Luteijn; Manuela A Timmermans; Eduard Vieta; Willem A Nolen Journal: J Clin Psychiatry Date: 2008-12-30 Impact factor: 4.384
Authors: Lakshmi N Yatham; Sidney H Kennedy; Ayal Schaffer; Sagar V Parikh; Serge Beaulieu; Claire O'Donovan; Glenda MacQueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Allan H Young; Martin Alda; Roumen Milev; Eduard Vieta; Joseph R Calabrese; Michael Berk; Kyooseob Ha; Flávio Kapczinski Journal: Bipolar Disord Date: 2009-05 Impact factor: 6.744
Authors: Ariel Gildengers; Curtis Tatsuoka; Christopher Bialko; Kristin A Cassidy; Philipp Dines; James Emanuel; Rayan K Al Jurdi; Laszlo Gyulai; Benoit H Mulsant; Robert C Young; Martha Sajatovic Journal: Cut Edge Psychiatry Pract Date: 2013
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk Journal: Bipolar Disord Date: 2018-03-14 Impact factor: 6.744
Authors: Ariel Gildengers; Curtis Tatsuoka; Christopher Bialko; Kristin A Cassidy; Rayan K Al Jurdi; Laszlo Gyulai; Benoit H Mulsant; Robert C Young; Martha Sajatovic Journal: J Geriatr Psychiatry Neurol Date: 2012-03 Impact factor: 2.680
Authors: Patricia Marino; Herbert C Schulberg; Ariel G Gildengers; Benoit H Mulsant; Martha Sajatovic; Laszlo Gyulai; Rayan K Aljurdi; Laurie Davan Evans; Samprit Banerjee; Ruben C Gur; Robert C Young Journal: Int J Geriatr Psychiatry Date: 2017-05-22 Impact factor: 3.485
Authors: Martha Sajatovic; Sergio A Strejilevich; Ariel G Gildengers; Annemiek Dols; Rayan K Al Jurdi; Brent P Forester; Lars Vedel Kessing; John Beyer; Facundo Manes; Soham Rej; Adriane R Rosa; Sigfried Ntm Schouws; Shang-Ying Tsai; Robert C Young; Kenneth I Shulman Journal: Bipolar Disord Date: 2015-09-19 Impact factor: 6.744